Loading clinical trials...
Loading clinical trials...
This study was designed to evaluate and compare safety, tolerability of subjects who successfully suppress HIV-1 on their first PI regimen to those who switch to fosamprenavir. This is a 48-week study...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
ViiV Healthcare
Collaborators
NCT00044577 · Infection, Human Immunodeficiency Virus I, HIV Infection
NCT01263015 · Infection, Human Immunodeficiency Virus I
NCT00104429 · Infection, Human Immunodeficiency Virus I, HIV Infection
NCT00082394 · Infection, Human Immunodeficiency Virus I, HIV Infection
NCT01283100 · Infection, Human Immunodeficiency Virus I
GSK Investigational Site
Beverly Hills, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Laguna Beach, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions